Compliance News | November 19, 2026

Final Rule on Pharmacy Benefit Manager Fee Disclosure

The DOL published a final rule designed to increase transparency regarding pharmacy benefit management services and compensation arrangements. The rule requires pharmacy benefit managers (PBMs) and affiliated brokers and consultants to provide specific disclosures regarding services, fees and compensation to fiduciaries of certain large, self-funded group health plans, as well as to provide related information upon request.

Final Rule on Pharmacy Benefit Manager Fee Disclosure

The final rule grants plan fiduciaries broad audit rights to support plans in verifying the accuracy of the disclosures and includes an important administrative exemption for responsible plan fiduciaries when a service provider fails to comply with the regulation.

The final rule is applicable for plan years beginning on or after July 1, 2027, therefore January 1, 2028, for calendar-year plans.

The final rule will provide plan sponsors with significantly greater visibility into PBM compensation and financial arrangements. With more detailed and standardized information, plan sponsors will be better positioned to assess the reasonableness of current and prospective contracts with PBMs and other covered service providers (CSPs). Plan sponsors should have greater ability to evaluate offers from different service providers, negotiate terms that are most aligned with the best interests of plan participants and maintain visibility and control over existing relationships.

Background on PBM disclosure requirements

The DOL issued a proposed fee disclosure rule in January 2026. Shortly after that, on February 3, 2026, the Consolidated Appropriations Act of 2026 (CAA) was signed into law, enacting additional reforms to PBM practices. (Our February 11, 2026 insight, “New Requirements for PBM Reporting and Fee Disclosures,” discusses both the proposed rule and the PBM reforms under the CAA.) Specifically, the CAA made changes to ERISA by amending ERISA Section 408(b)(2)(B) and adding new ERISA Sections 408(b)(2)(C) and 726.

The disclosures required under new Section 726 of ERISA overlap in certain respects with, and complement, the disclosures under the DOL fee disclosure rules, which the DOL addresses in the fee disclosure final rule.

The CAA also includes broader PBM reforms applicable to both self-funded and insured group health plans and issuers through amendments to ERISA, the Public Health Service Act and the Internal Revenue Code, which are generally administered by the Departments of Labor, Health and Human Services and the Treasury (collectively, the Departments). The CAA also amends ERISA Section 408(b)(2) to provide that for plans subject to ERISA, PBMs must pass 100 percent of all rebates, fees, alternative discounts and other remuneration to the group health plan or insurer.

In addition to CAA amendments to ERISA Section 408(b)(2) relating to PBM disclosures, the statute also requires third-party administrators and certain other entities providing services to group health plans to disclose all direct and indirect compensation received by the service provider to the group health plan sponsor. However, the scope of the Department's final rule is limited to disclosures and specifically disclosures by providers of pharmacy benefit management services and affiliated providers of consulting or brokerage services. The CAA also includes additional PBM reforms that apply to Medicare and Medicaid. Future regulatory guidance is expected to further implement the reforms enacted under the CAA applicable to plans and insurers, along with additional PBM reforms that apply to Medicare and Medicaid.

The final rule on PBM fee disclosures

The Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure final rule was published in the Federal Register on November 2, 2026. The final rule implements updated standards under Section 408(b)(2) of ERISA, which governs activities that are prohibited transactions under ERISA, unless certain requirements are met. The final PBM fee disclosure rule is an outgrowth of Executive Order 14273 directing initiatives to lower drug prices (discussed in our April 23, 2025 insight, “Executive Order Seeks to Lower Prescription Drug Prices”) and builds upon the proposed rule. The final rule applies to ERISA-covered plans and is designed to give fiduciaries of certain large, self-insured group health plans greater transparency into PBM compensation and financial arrangements to assess the reasonableness of service arrangements under ERISA.

The DOL revised certain provisions under the proposed PBM fee disclosure rule to better align the implementation and enforcement of the DOL fee disclosure requirements with the CAA. Specifically, the rule applies to the self-funded plan of “specified” large employers (generally those with at least 100 employees) and to self-insured “specified” large plans (generally those with at least 100 participants). Employers with fully insured plans that meet the size specifications can opt in to receive the required reporting.

As detailed below, the rule requires PBMs and affiliated brokers and consultants to provide certain plans with initial and ongoing information about the services being provided and related fees and compensation. Certain additional information must be made available upon request, and plans have audit rights to support monitoring the accuracy and completeness of the required disclosures.

In the final rule, the DOL explains that in contrast to the retrospective disclosures and drug spending and utilization disclosures required under Section 726 of ERISA, the disclosure requirements under the DOL fee disclosure rule (required initially and upon renewal with additional semiannual reporting) serve a distinct function aimed at improving transparency for purposes of large self-insured group health plan contracting practices involving providers of pharmacy benefit management services. The DOL also points to congressional amendments to ERISA Section 408(b)(2)(B) as consistent with the DOL fee disclosure rule and highlights that the CAA provided specific authority to the DOL to issue regulations addressing time, manner and content of the 408(b)(2) disclosures.

The final rule applies to PBMs and PBM-affiliated brokers and consultants providing pharmacy benefit management services (collectively, CSPs) that serve large, self-insured group health plans and expect to receive at least $1,000 in compensation. Under the final rule, PBM services include rebate negotiations, formulary and network management, and performing utilization review and management. PBM services can also include claims processing, appeals, recordkeeping and compliance functions but only when performed in connection with the core PBM activities.

Along with the final rule, the DOL issued a resource called Top 5 FAQs about the final rule and a Fact Sheet that presents an overview of the final rule.

Initial disclosures

CSPs must provide initial written disclosures to plan fiduciaries before entering into, extending or renewing a contract or arrangement. For renewals or extensions, disclosures must be provided at least 90 days in advance. These initial disclosures must provide a description of:

  • Services covered under the contract. This includes PBM services or advice, recommendations or referrals regarding those services.
  • Direct compensation. Direct compensation from the plan covers compensation in total and by service.
  • Indirect compensation. This refers to payments a CSP receives from sources other than the plan, specifically:
    • Manufacturer payments, including rebates, fees and other remuneration both in the aggregate and for each drug on the formulary
    • Spread compensation for each pharmacy channel, both in the aggregate and for each drug on the formulary
    • Pharmacy recoupments, such as expected claw-backs and other recoupments
    • Price protection arrangements

For each category, the CSP must disclose the compensation it reasonably expects to receive, payment sources, the related services and any other payment arrangements.

  • Other compensation. Any other compensation reasonably expected to be received in connection with PBM services, including who pays, the related services and the arrangement under which it is paid must be disclosed.
  • Formulary placement incentives. Manufacturer-related formulary incentives, including how they benefit the plan, must be disclosed. If the CSP retains manufacturer payments, it must identify available therapeutically equivalent alternatives (including biosimilar biological products) and explain why omitted products were excluded. The CSP also must disclose its authority to change the formulary, provide advance notice of material changes and disclose the plan’s right to terminate the contract.
  • Drug pricing methodology. This refers to the net price the plan pays for each formulary drug by pharmacy channel, after rebates, fees, discounts and other remuneration. If the net price cannot be determined, the CSP must disclose the pricing methodology and an objective means for the plan to verify it.
  • Statement of fiduciary status. This statement must identify whether the CSP or any affiliate, agent or subcontractor provides services as an ERISA fiduciary.
  • Statement of audit right. This statement must describe the plan's audit rights and procedures for requesting an audit.

Ongoing disclosures

The final rule aligns its ongoing disclosure framework with the CAA by requiring semiannual disclosures, with quarterly reporting available upon a plan’s request. To support ongoing fiduciary oversight of the CSP arrangements, the CSP must provide semiannual disclosures (or quarterly, upon the plan’s request) reporting compensation actually received and compensation expected to be received for the reporting period.

Disclosures are due within 30 days after the end of each reporting period. The reporting must include an explanation for any compensation category that materially exceeds the initial estimate (any 5 percent difference between actual compensation and amounts disclosed in the initial disclosures), including the amount and reason for the overage.

Information upon request

Upon written request, a CSP must provide any information relating to its contract or arrangement that is needed for the plan to comply with ERISA reporting and disclosure requirements, such as Form 5500 and Prescription Drug Data Collection (RxDC) reporting. The information must be provided sufficiently in advance of applicable filing deadlines unless extraordinary circumstances beyond the provider's control prevent timely disclosure.

Plan fiduciary audit rights

The final rule gives plans audit rights, including the ability to select any auditor, obtain records, claims and transaction-level data, and to require the PBM to acknowledge audit requests within 10 business days and provide requested information within 60 calendar days (absent extraordinary circumstances).

The rule states that while plans must periodically monitor service providers and ensure their compensation remains reasonable, they are not required to conduct an audit. In the absence of any signals that a service provider's compensation, fees or reporting fail to comply with the rules, a fiduciary may justifiably conclude that the cost of an audit outweighs its potential value. However, plans should monitor for any potential signs that a service provider may be failing to comply, signaling that an audit may be warranted.

Manner of disclosure

The disclosures from CSPs to plan fiduciaries must be:

  • Provided in plain language. Disclosures must be clear, concise, free of misrepresentations and specific enough for plans to assess the reasonableness of the arrangement. Undefined jargon, generic industry terms and legalese generally are not permitted unless tied to objective definitions or guidance that is publicly available or provided to the plan by the CSP upon request.
  • Expressed as a monetary amount. If the actual monetary amount is not reasonably ascertainable, it may be estimated using good-faith assumptions based on contract terms, historical utilization, rebate experience or other available information.
  • In a machine-readable format upon request. At the request of a plan fiduciary, the CSP must provide compensation disclosures in a standard machine-readable format within a reasonable time to support fiduciary analysis, benchmarking and oversight. Service agreements cannot restrict a fiduciary’s ability to request this format.
  • Shareable. CSPs generally cannot restrict a plan’s use of required disclosures or its ability to share them with advisers, consultants, attorneys, auditors or regulators. Reasonable confidentiality agreements may be required to prevent redisclosure and limit use to plan-related purposes.

Administrative class exemption

Failure to satisfy the rule’s disclosure or audit requirements may cause the arrangement to lose the protection of ERISA's prohibited transaction exemption. A fiduciary may qualify for an administrative exemption if it reasonably believed the PBM was compliant before discovering the failure and then takes the required corrective steps, including requesting correction and reporting unresolved noncompliance to the DOL. The rule advises that if the failure is not cured within 90 days, the fiduciary must determine whether to continue or terminate the arrangement and document that decision. The exemption does not alter the fiduciary's ongoing duties of prudence and loyalty under ERISA.

Applicability

The final rule is applicable for plan years beginning on or after July 1, 2027 (for calendar-year plans, January 1, 2028,). Although the CAA amendments to ERISA Section 408(b)(2)(B) became effective on February 3, 2026, the DOL has provided transition relief. To support coordination of implementation, the DOL clarified that between February 3, 2026 and the applicability date of the final rule, it will not treat a CSP as having failed to make the required disclosures to a responsible plan fiduciary under ERISA Section 408(b)(2)(B) as long as the CSP made disclosures based on a good-faith interpretation of its obligations under the law.

Similarly, prior to the applicability date of the final rule, the DOL will not treat a responsible plan fiduciary as having engaged in a prohibited transaction in entering into a contract or arrangement with a CSP, provided the fiduciary acted in accordance with a good-faith interpretation of their obligations under ERISA to determine the reasonableness of the contract or arrangement.

Next steps for sponsors of group health plans

Most plans rely on third-party PBMs and affiliated consultants and brokers. Plan sponsors should begin to identify the service providers they work with that are implicated by this law and discuss preparedness for compliance with the new requirements. Plan sponsors may consider revisions to requests for proposals and contract language with CSPs to account for compliance with the new rule.

Fiduciaries will need to review and monitor the required disclosures once they are available. Plans may evaluate PBM services, fees and compensation to help negotiate reasonable terms on behalf of the plan. Plans can assess whether additional information or audits are warranted and take appropriate action when compliance issues arise. Oversight of the disclosures as required by the final rule will be a central part of fiduciary governance. Therefore, plans should develop an approach to monitoring CSP compliance that includes a process for performing and documenting oversight of service providers. Plan sponsors should continue to watch for additional PBM-reform-related guidance under the CAA.

Have questions about the final rule on PBM fee disclosure?

We have answers.

Get in Touch

See more insights

Business Partners Cooperating At The Small Modern Office

Q4 2026 Trends Focus: Transparency in Coverage

See how Transparency in Coverage data can help health plan sponsors evaluate network pricing, identify savings and strengthen fiduciary oversight.
Young Couple Going Over Financial Documents At Home

Final Rule on Healthcare Transparency in Coverage

Learn how the Transparency in Coverage final rule affects disclosure requirements, price comparison tools and implementation planning.
Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.